Sectors
PTGX
Protagonist Therapeutics, Inc.
149.09
1 x 148.97
1 x 151.26
bid
ask
-
0.91
0.61%
09:40 AM
timesize
| Ytd | 70.69% | |
| 1y | 177.37% |
149.29
day range
152.00
53.49
52 week range
152.00
| Open | 151.88 | Prev Close | 150.00 | Low | 149.29 | High | 152.00 | Mkt Cap | 9.66B |
| Vol | 12.13K | Avg Vol | 690.55K | EPS | 1.03 | P/E | 145.82 | Forward P/E | -19527.40 |
| Beta | 1.78 | Short Ratio | 8.67 | Inst. Own | 125.37% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 124.41 | 200-d Avg | 99.25 | 1yr Est | 152.46 |
| Income Statement | |||
| Total Revenue | 213.48M | ||
| Revenues (USD) | 213.48M | ||
| Gross Profit | 213.48M | ||
| Operating Expenses | 54.71M | ||
| Research and Development Expense | 42.06M | ||
| Selling, General and Administrative Expense | 12.65M | ||
| Operating Income | 158.77M | ||
| Income Tax Expense | 2.27M | ||
| Net Income | 162.85M | ||
| Net Income Common Stock | 162.85M | ||
| Net Income Common Stock (USD) | 162.85M | ||
| Consolidated Income | 162.85M | ||
| Earnings per Basic Share | 2.47 | ||
| Earnings per Basic Share (USD) | 2.47 | ||
| Earnings per Diluted Share | 2.29 | ||
| Earning Before Interest & Taxes (EBIT) | 165.11M | ||
| Earning Before Interest & Taxes (USD) | 165.11M | ||
| Weighted Average Shares | 65.94M | ||
| Weighted Average Shares Diluted | 71.01M | ||
| Balance Sheet | |||
| Cash and Equivalents | 420.08M | ||
| Cash and Equivalents (USD) | 420.08M | ||
| Investments | 429.37M | ||
| Investments Current | 362.50M | ||
| Investments Non-Current | 66.88M | ||
| Trade and Non-Trade Receivables | 13.42M | ||
| Current Assets | 807.15M | ||
| Property, Plant & Equipment Net | 10.40M | ||
| Total Assets | 885.54M | ||
| Debt Current | 2.40M | ||
| Total Debt | 9.22M | ||
| Current Liabilities | 37.18M | ||
| Debt Non-Current | 6.82M | ||
| Total Liabilities | 44.00M | ||
| Accumulated Retained Earnings (Deficit) | -304.04M | ||
| Accumulated Other Comprehensive Income | -828.00K | ||
| Shareholders Equity | 841.54M | ||
| Shareholders Equity (USD) | 841.54M | ||
| Assets Non-Current | 78.40M | ||
| Total Debt (USD) | 9.22M | ||
| Deferred Revenue | 9.66M | ||
| Liabilities Non-Current | 6.82M | ||
| Trade and Non-Trade Payables | 3.46M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 841.00K | ||
| Net Cash Flow from Financing | 9.74M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 226.37M | ||
| Capital Expenditure | -168.00K | ||
| Net Cash Flow from Investing | -2.43M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -2.26M | ||
| Net Cash Flow from Operations | 219.05M | ||
| Share Based Compensation | 14.04M | ||